Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE EFFECTS OF A SELECTIVE D-4 DOPAMINE-RECEPTOR ANTAGONIST (L-745,870) IN ACUTELY PSYCHOTIC INPATIENTS WITH SCHIZOPHRENIA
Autore:
KRAMER MS; LAST B; GETSON A; REINES SA; SILVA JA; WIRSHING W; CONLEY R; ALLAN E; CHENG HY; CHAVEZENG C;
Indirizzi:
MERCK & CO INC,DEPT CLIN NEUROSCI W POINT PA 00000 MERCK & CO INC,DEPT CLIN BIOSTAT W POINT PA 00000 THOMAS JEFFERSON MED COLL,DEPT PSYCHIAT & HUMAN BEHAV PHILADELPHIA PA00000 LOMA LINDA UNIV,BEHAV MED CTR REDLANDS CA 00000 CHARTER BROOKSIDE HOSP NASHUA NH 00000 NEW YORK VET ADM MED CTR NEW YORK NY 00000 JOHN UMSTEAD HOSP BUTNER NC 00000 HILLSIDE HOSP GLEN OAKS NY 11004 LONG ISL JEWISH MED CTR GLEN OAKS NY 11004 LONG ISL JEWISH MED CTR GLEN OAKS NY 00000 AFFILIATED RES INST SAN DIEGO CA 00000 UNIV TEXAS,HLTH SCI CTR SAN ANTONIO TX 00000 VET ADM MED CTR LOS ANGELES CA 00000 UNIV CALIF LOS ANGELES LOS ANGELES CA 00000
Titolo Testata:
Archives of general psychiatry
fascicolo: 6, volume: 54, anno: 1997,
pagine: 567 - 572
SICI:
0003-990X(1997)54:6<567:TEOASD>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
D4 RECEPTORS; H-3 NEMONAPRIDE; CLOZAPINE; ELEVATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
21
Recensione:
Indirizzi per estratti:
Citazione:
M.S. Kramer et al., "THE EFFECTS OF A SELECTIVE D-4 DOPAMINE-RECEPTOR ANTAGONIST (L-745,870) IN ACUTELY PSYCHOTIC INPATIENTS WITH SCHIZOPHRENIA", Archives of general psychiatry, 54(6), 1997, pp. 567-572

Abstract

Background: Based mainly on the selective antagonism of clozapine at D-4 compared with D-2 dopamine receptors, hopes have run high that a selective D-4 dopamine receptor antagonist might improve the pharmacological treatment of patients with schizophrenia. We report, to our knowledge, the first multicenter study of the antipsychotic potential of ahighly specific D, dopamine receptor antagonist tie, L-745,870) in patients with acute schizophrenia. Methods: Thirty-eight acutely psychotic and neuroleptic responsive (by history) newly admitted inpatients with schizophrenia were randomized to 4 weeks of double-blind treatment(2:1) with either L-745,870 (n = 26), 15 mg/d, or placebo (n = 12) after a 3- to 5-day placebo run-in period. Results: Overall, a greater percentage of patients receiving L-745,870 compared with patients receiving placebo discontinued the study for insufficient therapeutic response (32% vs 16%). At the end of 4 weeks by last observation carried forward analysis, the mean change from baseline to week 4 on the total Brief Psychiatric Rating Scale favored placebo (ie, -8 points [-15% change from baseline] vs -1 point [-2% change from baseline] for placebo vs L-745,870, P = .09). Similar differences in favor of placebo in changes from baseline mean scores were observed for the not carried forward analysis on the total Brief Psychiatric Rating Scale (P < .03), fornot carried forward and last observation carried forward analyses on the sum of selected positive symptom items of the Brief Psychiatric Rating Scale, and for the Clinical Global Impression analysis (P = .03, last observation carried forward). A greater percentage of patients receiving L-745,870 had scores indicative of some level of worsening (compared with baseline) on the total Brief Psychiatric Rating Scale and the Clinical Global Impressions' Severity of Illness Scale as well as positive symptoms compared with those receiving placebo. Conclusion: The selective D-4 dopamine receptor antagonist L-745,870 was ineffective as an antipsychotic for the treatment of neuroleptic responsive inpatients with acute schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 01:22:36